sitagliptin

CLINICAL USE

Treatment of type 2 diabetes in combination with metformin or a thiazolidinedione

DOSE IN NORMAL RENAL FUNCTION

100 mg once daily

PHARMACOKINETICS

Molecular weight :523.3 (as phosphate)

%Protein binding :38

%Excreted unchanged in urine : 79

Volume of distribution (L/kg) :198 litres

half-life – normal/ESRD (hrs) :12.4/Probably increased

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

30–50 50 mg once daily<30 25 mg once daily

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Not dialysed. Dose as in GFR>30 mL/min

HD :Not dialysed. Dose as in GFR>30 mL/min

HDF/high flux :Dialysed. Dose as in GFR>30 mL/min

CAV/VVHD :Unknown dialysability. Dose as in GFR>30 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

13.5% of dose is removed during a 3–4 hour haemodialysis sessionIn severe renal impairment (GFR<30 mL/min) the AUC was increased 4-fold50 mg and 25 mg tablets are only available in the USA at present.

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home